MRSA is a common cause of hospital-acquired infections and can lead to serious illness and death. CDC data shows that about 5 percent of hospital patients carry MRSA, though not all carriers develop an infection.
MRSA is resistant to many common antibiotics, so infections can be very hard to treat and control. The CDC estimates that there were more than 10,000 MRSA-related deaths in 2017.
The new test, called the cobas vivoDx MRSA test, tests for MRSA in as little as five hours, compared to 24-48 hours for traditional MRSA tests. It uses bacteriophage technology based on bioluminescence to detect MRSA from nasal swabs.
In performance studies, cobas vivoDx correctly identified MRSA in about 90 percent of samples where MRSA was present, and correctly identified no MRSA in 98.6 percent of samples that did not have MRSA present.
Read the full news release here.
More articles on supply chain:
Viant to shut down sterilization operations at Michigan facility
Hahnemann hospital auctioning off medical equipment, supplies
UPS names president of healthcare unit
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.